|
US6440457B1
(en)
*
|
1993-05-27 |
2002-08-27 |
Alza Corporation |
Method of administering antidepressant dosage form
|
|
US5837284A
(en)
*
|
1995-12-04 |
1998-11-17 |
Mehta; Atul M. |
Delivery of multiple doses of medications
|
|
US5922736A
(en)
*
|
1995-12-04 |
1999-07-13 |
Celegene Corporation |
Chronic, bolus administration of D-threo methylphenidate
|
|
US6486177B2
(en)
*
|
1995-12-04 |
2002-11-26 |
Celgene Corporation |
Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate
|
|
US6355656B1
(en)
*
|
1995-12-04 |
2002-03-12 |
Celgene Corporation |
Phenidate drug formulations having diminished abuse potential
|
|
US8071128B2
(en)
|
1996-06-14 |
2011-12-06 |
Kyowa Hakko Kirin Co., Ltd. |
Intrabuccally rapidly disintegrating tablet and a production method of the tablets
|
|
US6919373B1
(en)
*
|
1996-11-12 |
2005-07-19 |
Alza Corporation |
Methods and devices for providing prolonged drug therapy
|
|
US6962997B1
(en)
*
|
1997-05-22 |
2005-11-08 |
Celgene Corporation |
Process and intermediates for resolving piperidyl acetamide steroisomers
|
|
US5945123A
(en)
*
|
1998-04-02 |
1999-08-31 |
K-V Pharmaceutical Company |
Maximizing effectiveness of substances used to improve health and well being
|
|
US20040062802A1
(en)
*
|
1998-04-02 |
2004-04-01 |
Hermelin Victor M. |
Maximizing effectiveness of substances used to improve health and well being
|
|
ATE277594T1
(de)
*
|
1998-06-03 |
2004-10-15 |
Alza Corp |
Vorrichtungen um eine verlängerte medikamententherapie zu erreichen
|
|
AU2004200325B2
(en)
*
|
1998-10-21 |
2006-09-28 |
Shire Llc |
Oral Pulsed Dose Drug Delivery System
|
|
US6322819B1
(en)
|
1998-10-21 |
2001-11-27 |
Shire Laboratories, Inc. |
Oral pulsed dose drug delivery system
|
|
US20060240105A1
(en)
*
|
1998-11-02 |
2006-10-26 |
Elan Corporation, Plc |
Multiparticulate modified release composition
|
|
US20090149479A1
(en)
*
|
1998-11-02 |
2009-06-11 |
Elan Pharma International Limited |
Dosing regimen
|
|
KR20070051953A
(ko)
*
|
1998-11-02 |
2007-05-18 |
엘란 코포레이션, 피엘씨 |
다입자 변형 방출 조성물
|
|
US20080118556A1
(en)
*
|
1998-11-02 |
2008-05-22 |
Elan Corporation, Plc |
Modified Release of Compositions Containing a Combination of Carbidopa, Levodopa and Entacapone
|
|
US7083808B2
(en)
*
|
1998-12-17 |
2006-08-01 |
Euro-Celtique S.A. |
Controlled/modified release oral methylphenidate formulations
|
|
US6673367B1
(en)
*
|
1998-12-17 |
2004-01-06 |
Euro-Celtique, S.A. |
Controlled/modified release oral methylphenidate formulations
|
|
US6419960B1
(en)
*
|
1998-12-17 |
2002-07-16 |
Euro-Celtique S.A. |
Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
|
|
US6395752B1
(en)
*
|
1999-03-04 |
2002-05-28 |
Pharmaquest Limited |
Method of treating depression using 1-threo-methylphenidate
|
|
US6127385A
(en)
*
|
1999-03-04 |
2000-10-03 |
Pharmaquest Limited |
Method of treating depression using l-threo-methylphenidate
|
|
EP1165054A4
(en)
|
1999-04-06 |
2005-02-09 |
Pharmaquest Ltd |
PHARMACEUTICAL DOSAGE FORM FOR INTERMITTENT DELIVERY OF METHYLPHENIDATE
|
|
US20030170181A1
(en)
*
|
1999-04-06 |
2003-09-11 |
Midha Kamal K. |
Method for preventing abuse of methylphenidate
|
|
US6730349B2
(en)
|
1999-04-19 |
2004-05-04 |
Scimed Life Systems, Inc. |
Mechanical and acoustical suspension coating of medical implants
|
|
US6368658B1
(en)
|
1999-04-19 |
2002-04-09 |
Scimed Life Systems, Inc. |
Coating medical devices using air suspension
|
|
GB9913458D0
(en)
*
|
1999-06-09 |
1999-08-11 |
Medeva Europ Ltd |
The therapeutic use of d-threo-methylphenidate
|
|
EP1064937A1
(en)
*
|
1999-06-28 |
2001-01-03 |
Sanofi-Synthelabo |
Timed dual release dosage forms comprising a short acting hypnotic or a salt thereof
|
|
US10179130B2
(en)
|
1999-10-29 |
2019-01-15 |
Purdue Pharma L.P. |
Controlled release hydrocodone formulations
|
|
KR20020059653A
(ko)
|
1999-10-29 |
2002-07-13 |
그린 마틴, 브라이언 쥐 테슬리 |
서방성 하이드로코돈 제형
|
|
DE60115840T2
(de)
*
|
2000-01-19 |
2006-07-13 |
Mannkind Corp., Danbury |
Formulierung mit mehrfach gepulster wirkstofffreisetzung
|
|
US6627223B2
(en)
|
2000-02-11 |
2003-09-30 |
Eurand Pharmaceuticals Ltd. |
Timed pulsatile drug delivery systems
|
|
US6544555B2
(en)
|
2000-02-24 |
2003-04-08 |
Advancis Pharmaceutical Corp. |
Antibiotic product, use and formulation thereof
|
|
US6565882B2
(en)
|
2000-02-24 |
2003-05-20 |
Advancis Pharmaceutical Corp |
Antibiotic composition with inhibitor
|
|
US7674480B2
(en)
*
|
2000-06-23 |
2010-03-09 |
Teva Pharmaceutical Industries Ltd. |
Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
|
|
US6881420B2
(en)
|
2000-06-23 |
2005-04-19 |
Teva Pharmaceutical Industries Ltd. |
Compositions and dosage forms for gastric delivery of irinotecan and methods of treatment that use it to inhibit cancer cell proliferation
|
|
US6476006B2
(en)
|
2000-06-23 |
2002-11-05 |
Teva Pharmaceutical Industries, Ltd. |
Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates
|
|
US6500457B1
(en)
|
2000-08-14 |
2002-12-31 |
Peirce Management, Llc |
Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent
|
|
US6541014B2
(en)
|
2000-10-13 |
2003-04-01 |
Advancis Pharmaceutical Corp. |
Antiviral product, use and formulation thereof
|
|
US20020068078A1
(en)
|
2000-10-13 |
2002-06-06 |
Rudnic Edward M. |
Antifungal product, use and formulation thereof
|
|
US6344215B1
(en)
*
|
2000-10-27 |
2002-02-05 |
Eurand America, Inc. |
Methylphenidate modified release formulations
|
|
US6733783B2
(en)
|
2000-10-30 |
2004-05-11 |
Euro-Celtique S.A. |
Controlled release hydrocodone formulations
|
|
AU2002221412B2
(en)
*
|
2000-12-05 |
2006-04-13 |
Alexander Macgregor |
Hydrostatic delivery system for controlled delivery of agent
|
|
EP1368000A4
(en)
|
2001-03-13 |
2004-12-01 |
Penwest Pharmaceuticals Co |
CHRONOTHERAPEUTIC PHARMACEUTICAL FORMS CONTAINING A GLUCOCORTICOSTEROID
|
|
US20020187192A1
(en)
*
|
2001-04-30 |
2002-12-12 |
Yatindra Joshi |
Pharmaceutical composition which reduces or eliminates drug abuse potential
|
|
US20030049272A1
(en)
*
|
2001-08-30 |
2003-03-13 |
Yatindra Joshi |
Pharmaceutical composition which produces irritation
|
|
US9358214B2
(en)
|
2001-10-04 |
2016-06-07 |
Adare Pharmaceuticals, Inc. |
Timed, sustained release systems for propranolol
|
|
US6500454B1
(en)
*
|
2001-10-04 |
2002-12-31 |
Eurand Pharmaceuticals Ltd. |
Timed, sustained release systems for propranolol
|
|
US20050025824A1
(en)
*
|
2001-12-14 |
2005-02-03 |
Eurand Pharmaceuticals Ltd. |
Pulsatile release histamine H2 antagonist dosage form
|
|
US6663888B2
(en)
*
|
2001-12-14 |
2003-12-16 |
Eurand Pharmaceuticals Ltd. |
Pulsatile release histamine H2 antagonist dosage form
|
|
US6638533B2
(en)
|
2002-01-03 |
2003-10-28 |
George Krsek |
Pulse dosage formulations of methylphenidate and method to prepare same
|
|
US20030165614A1
(en)
*
|
2002-03-01 |
2003-09-04 |
Henrik Hansen |
Coating a medical implant using a pan coater
|
|
US20050232995A1
(en)
|
2002-07-29 |
2005-10-20 |
Yam Nyomi V |
Methods and dosage forms for controlled delivery of paliperidone and risperidone
|
|
CA2395819A1
(en)
*
|
2002-08-13 |
2004-02-13 |
Bernard Charles Sherman |
Dual-spike release formulation for oral drug delivery
|
|
US20060039974A1
(en)
|
2002-09-11 |
2006-02-23 |
Takeda Pharmaceutical Company Limited |
Sustained release preparation
|
|
US6913768B2
(en)
*
|
2002-09-24 |
2005-07-05 |
Shire Laboratories, Inc. |
Sustained release delivery of amphetamine salts
|
|
US20080220074A1
(en)
*
|
2002-10-04 |
2008-09-11 |
Elan Corporation Plc |
Gamma radiation sterilized nanoparticulate docetaxel compositions and methods of making same
|
|
US20040109889A1
(en)
*
|
2002-12-04 |
2004-06-10 |
Bunick Frank J. |
Surface treatment composition for soft substrates
|
|
US7988993B2
(en)
*
|
2002-12-09 |
2011-08-02 |
Andrx Pharmaceuticals, Inc. |
Oral controlled release dosage form
|
|
HUE026034T2
(en)
|
2002-12-13 |
2016-05-30 |
Durect Corp |
Oral delivery system containing an oral high-viscosity carrier
|
|
US8367111B2
(en)
|
2002-12-31 |
2013-02-05 |
Aptalis Pharmatech, Inc. |
Extended release dosage forms of propranolol hydrochloride
|
|
WO2005009368A2
(en)
|
2003-07-21 |
2005-02-03 |
Advancis Pharmaceutical Corporation |
Antibiotic product, use and formulation thereof
|
|
CA2533358C
(en)
|
2003-07-21 |
2014-03-11 |
Advancis Pharmaceutical Corporation |
Antibiotic product, use and formulation thereof
|
|
WO2005009365A2
(en)
|
2003-07-21 |
2005-02-03 |
Advancis Pharmaceutical Corporation |
Antibiotic product, use and formulation thereof
|
|
JP2007502296A
(ja)
|
2003-08-11 |
2007-02-08 |
アドバンシス ファーマスーティカル コーポレイション |
ロバストペレット
|
|
US8062672B2
(en)
|
2003-08-12 |
2011-11-22 |
Shionogi Inc. |
Antibiotic product, use and formulation thereof
|
|
AU2004270170B2
(en)
*
|
2003-08-29 |
2011-01-27 |
Shionogi, Inc. |
Antibiotic product, use and formulation thereof
|
|
PL1667665T3
(pl)
*
|
2003-09-03 |
2009-06-30 |
Pharmaton Sa |
Kapsułki zawierające peletki z substancją czynną z różnymi profilami uwalniania
|
|
WO2005027877A1
(en)
|
2003-09-15 |
2005-03-31 |
Advancis Pharmaceutical Corporation |
Antibiotic product, use and formulation thereof
|
|
MXPA06003100A
(es)
|
2003-09-19 |
2006-06-20 |
Penwest Pharmaceuticals Co |
Formas de dosis de liberacion retardada.
|
|
US20090304793A1
(en)
*
|
2003-09-22 |
2009-12-10 |
Alpharma, Inc. |
Sustained release opioid formulations and methods of use
|
|
US20050187196A1
(en)
*
|
2004-02-23 |
2005-08-25 |
Saegis Pharmaceuticals, Inc. |
Treatment of attention disorders
|
|
US7404970B2
(en)
*
|
2004-04-13 |
2008-07-29 |
Konec, Inc. |
Pain relief composition, method to form same, and method to use same
|
|
US20050239830A1
(en)
*
|
2004-04-26 |
2005-10-27 |
Vikram Khetani |
Methods of diminishing co-abuse potential
|
|
ES2261006B1
(es)
*
|
2004-06-10 |
2007-11-01 |
Laboratorios Rubio, S.A. |
Pellet multicapa de liberacion controlada de metilfenidato.
|
|
EP1768668A2
(en)
|
2004-06-16 |
2007-04-04 |
Tap Pharmaceutical Products, Inc. |
Multiple ppi dosage form
|
|
WO2006014427A1
(en)
|
2004-07-02 |
2006-02-09 |
Advancis Pharmaceutical Corporation |
Tablet for pulsed delivery
|
|
WO2006012536A2
(en)
|
2004-07-22 |
2006-02-02 |
Ritter Andrew J |
Methods and compositions for treating lactose intolerance
|
|
DK1791530T3
(da)
*
|
2004-08-23 |
2008-10-27 |
Pejo Iserlohn Heilmittel Und D |
Farmaceutisk komposition indeholdende et psykostimulerende middel
|
|
US8747895B2
(en)
|
2004-09-13 |
2014-06-10 |
Aptalis Pharmatech, Inc. |
Orally disintegrating tablets of atomoxetine
|
|
US9884014B2
(en)
|
2004-10-12 |
2018-02-06 |
Adare Pharmaceuticals, Inc. |
Taste-masked pharmaceutical compositions
|
|
EP2417969A1
(en)
|
2004-10-21 |
2012-02-15 |
Aptalis Pharmatech, Inc. |
Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
|
|
WO2006063078A2
(en)
*
|
2004-12-08 |
2006-06-15 |
Elan Corporation, Plc |
Topiramate pharmaceuticals composition
|
|
CA2591247A1
(en)
*
|
2004-12-09 |
2006-06-15 |
Celgene Corporation |
Treatment of patients suffering from a disease having a family history or diagnosis of tics or tourette's syndrome with d-threo methylphenidate
|
|
GB0507298D0
(en)
|
2005-04-11 |
2005-05-18 |
Novartis Ag |
Organic compounds
|
|
CA2602268A1
(en)
*
|
2005-04-12 |
2006-10-19 |
Elan Pharma International Limited |
Controlled release compositions comprising a cephalosporin for the treatment of a bacterial infection
|
|
US9161918B2
(en)
|
2005-05-02 |
2015-10-20 |
Adare Pharmaceuticals, Inc. |
Timed, pulsatile release systems
|
|
WO2007070082A1
(en)
*
|
2005-05-10 |
2007-06-21 |
Elan Pharma International Limited |
Nanoparticulate and controlled release compositions comprising teprenone
|
|
WO2007037790A2
(en)
*
|
2005-06-08 |
2007-04-05 |
Elan Corporation, Plc |
Modified release famciclovir compositions
|
|
ZA200711123B
(en)
|
2005-06-27 |
2009-08-26 |
Biovail Lab Int Srl |
Modified-release formulations of a bupropion salt
|
|
JP5505760B2
(ja)
*
|
2005-09-27 |
2014-05-28 |
ティッシュテク・インコーポレーテッド |
羊膜調製物及び精製組成物及びその使用方法
|
|
US8187639B2
(en)
*
|
2005-09-27 |
2012-05-29 |
Tissue Tech, Inc. |
Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment
|
|
US20070104788A1
(en)
*
|
2005-11-10 |
2007-05-10 |
Seamus Mulligan |
Once-daily administration of central nervous system drugs
|
|
MX336930B
(es)
|
2005-11-28 |
2016-02-05 |
Marinus Pharmaceuticals |
Formulaciones de ganaxolona y metodos para la manufactura y el uso de las mismas.
|
|
US8357394B2
(en)
|
2005-12-08 |
2013-01-22 |
Shionogi Inc. |
Compositions and methods for improved efficacy of penicillin-type antibiotics
|
|
US8778924B2
(en)
|
2006-12-04 |
2014-07-15 |
Shionogi Inc. |
Modified release amoxicillin products
|
|
ZA200806496B
(en)
*
|
2006-01-27 |
2009-12-30 |
Eurand Inc |
Drug delivery systems comprising weakly basic drugs and organic acids
|
|
CN103211779B
(zh)
*
|
2006-01-27 |
2016-03-16 |
阿代尔制药股份有限公司 |
包含弱碱性选择性5-羟色胺5-ht3阻断剂和有机酸的药物递送系统
|
|
DK2018160T3
(da)
|
2006-03-16 |
2012-02-06 |
Tris Pharma Inc |
Modificeret depotformuleringer indeholdende lægemiddel-ionbytterharpikskomplekser
|
|
US8299052B2
(en)
|
2006-05-05 |
2012-10-30 |
Shionogi Inc. |
Pharmaceutical compositions and methods for improved bacterial eradication
|
|
US8846100B2
(en)
|
2006-05-12 |
2014-09-30 |
Shire Llc |
Controlled dose drug delivery system
|
|
WO2008021368A2
(en)
|
2006-08-11 |
2008-02-21 |
The Johns Hopkins University |
Compositions and methods for neuroprotection
|
|
DK2529622T3
(en)
|
2006-09-22 |
2018-05-07 |
Pharmacyclics Llc |
INHIBITORS OF BRUTON-TYROSINKINASE
|
|
PL2124556T3
(pl)
|
2006-10-09 |
2015-02-27 |
Charleston Laboratories Inc |
Kompozycje farmaceutyczne
|
|
WO2008061226A2
(en)
|
2006-11-17 |
2008-05-22 |
Supernus Pharmaceuticals Inc. |
Sustained-release formulations of topiramate
|
|
JP2010514777A
(ja)
|
2006-12-26 |
2010-05-06 |
ファーマサイクリックス，インク． |
併用療法においてヒストンデアセチラーゼ阻害剤を使用し、バイオマーカーをモニタする方法
|
|
BRPI0814409A2
(pt)
*
|
2007-07-06 |
2014-10-14 |
Nuon Therapeutics Inc |
Tratamento de dor neuropática
|
|
US8263641B2
(en)
|
2007-09-10 |
2012-09-11 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
|
EP2203068A4
(en)
|
2007-10-12 |
2012-08-22 |
Takeda Pharmaceuticals Usa Inc |
METHOD FOR THE TREATMENT OF STOMACH DARM DISEASES INDEPENDENT FROM FOOD STORAGE
|
|
JP2011506318A
(ja)
|
2007-12-06 |
2011-03-03 |
デュレクト コーポレーション |
経口医薬製剤
|
|
CA3066426A1
(en)
|
2008-01-09 |
2009-07-16 |
Charleston Laboratories, Inc. |
Pharmaceutical compositions comprising an antiemetic and an opioid analgesic
|
|
CA2627198A1
(en)
*
|
2008-03-27 |
2009-09-27 |
Pharmascience Inc. |
Methylphenidate extended release therapeutic drug delivery system
|
|
US20090311335A1
(en)
*
|
2008-06-12 |
2009-12-17 |
Scott Jenkins |
Combination of a triptan and an nsaid
|
|
US20100034968A1
(en)
*
|
2008-08-07 |
2010-02-11 |
Vector Corporation |
Polymer coating process using dry glidant in a rotor processor
|
|
US20100034967A1
(en)
*
|
2008-08-07 |
2010-02-11 |
Vector Corporation |
Dry polymer layering using a rotor processor
|
|
US8807070B2
(en)
*
|
2008-08-07 |
2014-08-19 |
Vector Corporation |
Rotor processor for dry powders
|
|
CA2734500A1
(en)
|
2008-08-27 |
2010-03-11 |
Calcimedica Inc. |
Compounds that modulate intracellular calcium
|
|
US20100260844A1
(en)
|
2008-11-03 |
2010-10-14 |
Scicinski Jan J |
Oral pharmaceutical dosage forms
|
|
CN102238946B
(zh)
*
|
2008-11-07 |
2014-11-26 |
株式会社三养生物制药 |
用于哌醋甲酯的控制释放的药物组合物
|
|
WO2010071866A2
(en)
|
2008-12-19 |
2010-06-24 |
Nuon Therapeutics, Inc. |
Combination therapy for arthritis with tranilast
|
|
KR20170053733A
(ko)
|
2009-02-24 |
2017-05-16 |
리터 파마슈티컬즈 인코오포레이티드 |
프리바이오틱 제제 및 사용 방법
|
|
US8785160B2
(en)
|
2009-02-24 |
2014-07-22 |
Ritter Pharmaceuticals, Inc. |
Prebiotic formulations and methods of use
|
|
US20100227876A1
(en)
*
|
2009-03-06 |
2010-09-09 |
Rechfensen Llp |
Methods of Reducing Side Effects of Analgesics
|
|
US8603521B2
(en)
|
2009-04-17 |
2013-12-10 |
Pharmacyclics, Inc. |
Formulations of histone deacetylase inhibitor and uses thereof
|
|
ES2559029T3
(es)
|
2009-04-24 |
2016-02-10 |
Tissue Tech, Inc. |
Composiciones que contienen al complejo HC.HA y metodos de uso de las mismas
|
|
US20110003005A1
(en)
*
|
2009-07-06 |
2011-01-06 |
Gopi Venkatesh |
Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions
|
|
CA2767576C
(en)
|
2009-07-08 |
2020-03-10 |
Charleston Laboratories Inc. |
Pharmaceutical compositions comprising an antiemetic and an opioid analgesic
|
|
EP2462128B1
(en)
|
2009-08-04 |
2016-09-21 |
Amira Pharmaceuticals, Inc. |
Compounds as lysophosphatidic acid receptor antagonists
|
|
WO2011020032A2
(en)
*
|
2009-08-13 |
2011-02-17 |
Kudco Ireland, Ltd. |
Pharmaceutical dosage form
|
|
GB2474120B
(en)
|
2009-10-01 |
2011-12-21 |
Amira Pharmaceuticals Inc |
Compounds as Lysophosphatidic acid receptor antagonists
|
|
US7718662B1
(en)
|
2009-10-12 |
2010-05-18 |
Pharmacyclics, Inc. |
Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
|
|
WO2011067667A2
(en)
|
2009-12-02 |
2011-06-09 |
Eurand Pharmaceuticals Limited |
Fexofenadine microcapsules and compositions containing them
|
|
KR101819199B1
(ko)
|
2010-02-16 |
2018-01-16 |
아라곤 파마슈티컬스, 인코포레이티드 |
안드로겐 수용체 조절제 및 이의 용도
|
|
ES2602475T3
(es)
|
2010-04-15 |
2017-02-21 |
Tracon Pharmaceuticals, Inc. |
Potenciación de la actividad anticáncer por terapia de combinación con inhibidores de la vía BER
|
|
HUE029570T2
(en)
|
2010-04-27 |
2017-03-28 |
Calcimedica Inc |
Intracellular calcium modifying compounds
|
|
US8754219B2
(en)
|
2010-04-27 |
2014-06-17 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
|
WO2011143152A2
(en)
|
2010-05-11 |
2011-11-17 |
Questcor Pharmaceuticals |
Acth for treatment of amyotrophic lateral sclerosis
|
|
CA2800673A1
(en)
|
2010-06-10 |
2011-12-15 |
Aragon Pharmaceuticals, Inc. |
Estrogen receptor modulators and uses thereof
|
|
CN114591311A
(zh)
|
2010-08-27 |
2022-06-07 |
钙医学公司 |
调节细胞内钙的化合物
|
|
US8796416B1
(en)
|
2010-10-25 |
2014-08-05 |
Questcor Pharmaceuticals, Inc |
ACTH prophylactic treatment of renal disorders
|
|
CA2820817A1
(en)
|
2010-12-07 |
2012-06-14 |
Amira Pharmaceuticals, Inc. |
Lysophosphatidic acid receptor antagonists and uses thereof
|
|
US8287903B2
(en)
|
2011-02-15 |
2012-10-16 |
Tris Pharma Inc |
Orally effective methylphenidate extended release powder and aqueous suspension product
|
|
KR20140006879A
(ko)
*
|
2011-02-17 |
2014-01-16 |
에프. 호프만-라 로슈 아게 |
고온 용융 압출에 의해 활성 약학 성분을 과냉된 액체 상태로부터 제어되는 방식으로 결정화시키는 방법
|
|
US9283214B2
(en)
|
2011-03-23 |
2016-03-15 |
Ironshore Pharmaceuticals & Development, Inc. |
Compositions for treatment of attention deficit hyperactivity disorder
|
|
US9119809B2
(en)
|
2011-03-23 |
2015-09-01 |
Ironshore Pharmaceuticals & Development, Inc. |
Compositions for treatment of attention deficit hyperactivity disorder
|
|
US10905652B2
(en)
|
2011-03-23 |
2021-02-02 |
Ironshore Pharmaceuticals & Development, Inc. |
Compositions for treatment of attention deficit hyperactivity disorder
|
|
US9498447B2
(en)
|
2011-03-23 |
2016-11-22 |
Ironshore Pharmaceuticals & Development, Inc. |
Compositions for treatment of attention deficit hyperactivity disorder
|
|
US11241391B2
(en)
|
2011-03-23 |
2022-02-08 |
Ironshore Pharmaceuticals & Development, Inc. |
Compositions for treatment of attention deficit hyperactivity disorder
|
|
US10292937B2
(en)
|
2011-03-23 |
2019-05-21 |
Ironshore Pharmaceuticals & Development, Inc. |
Methods of treatment of attention deficit hyperactivity disorder
|
|
US9603809B2
(en)
|
2011-03-23 |
2017-03-28 |
Ironshore Pharmaceuticals & Development, Inc. |
Methods of treatment of attention deficit hyperactivity disorder
|
|
US8927010B2
(en)
|
2011-03-23 |
2015-01-06 |
Ironshore Pharmaceuticals & Development, Inc. |
Compositions for treatment of attention deficit hyperactivity disorder
|
|
US8916588B2
(en)
|
2011-03-23 |
2014-12-23 |
Ironshore Pharmaceuticals & Development, Inc. |
Methods for treatment of attention deficit hyperactivity disorder
|
|
EP4316488A3
(en)
*
|
2011-03-23 |
2024-02-28 |
Ironshore Pharmaceuticals & Development, Inc. |
Methods and compositions for treatment of attention deficit disorder
|
|
WO2012149486A1
(en)
|
2011-04-28 |
2012-11-01 |
Tissuetech, Inc. |
Methods of modulating bone remodeling
|
|
US9260416B2
(en)
|
2011-05-27 |
2016-02-16 |
Amira Pharmaceuticals, Inc. |
Heterocyclic autotaxin inhibitors and uses thereof
|
|
CA2837878A1
(en)
|
2011-06-10 |
2012-12-13 |
Tissuetech, Inc. |
Methods of processing fetal support tissues, fetal support tissue powder products, and uses thereof
|
|
EP2726066B1
(en)
|
2011-06-28 |
2021-03-31 |
Neos Therapeutics, LP |
Dosage forms of amphetamine for oral administration
|
|
KR101892788B1
(ko)
|
2011-09-13 |
2018-08-28 |
파마싸이클릭스 엘엘씨 |
벤다무스틴과 조합된 히스톤 디아세틸라제 억제제의 제제 및 그의 용도
|
|
US8377946B1
(en)
|
2011-12-30 |
2013-02-19 |
Pharmacyclics, Inc. |
Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
|
|
JP6154887B2
(ja)
|
2012-03-20 |
2017-06-28 |
セラゴン ファーマシューティカルズ，インク． |
エストロゲン受容体モジュレーターおよびその使用
|
|
JP2015528001A
(ja)
|
2012-07-11 |
2015-09-24 |
ティッシュテック，インク． |
Ｈｃ−ｈａ／ｐｔｘ３複合体を含む組成物およびその使用方法
|
|
AR091857A1
(es)
|
2012-07-25 |
2015-03-04 |
Sova Pharmaceuticals Inc |
INHIBIDORES DE CISTATIONIN-g-LIASA (CSE)
|
|
AR091858A1
(es)
|
2012-07-25 |
2015-03-04 |
Sova Pharmaceuticals Inc |
INHIBIDORES DE CISTATIONIN-g-LIASA (CSE)
|
|
CA2880456A1
(en)
|
2012-08-15 |
2014-02-20 |
Tris Pharma, Inc. |
Methylphenidate extended release chewable tablet
|
|
ES2836424T3
(es)
|
2012-09-26 |
2021-06-25 |
Aragon Pharmaceuticals Inc |
Antiandrógenos para tratar el cáncer de próstata no metastásico y resistente a la castración
|
|
US9416141B2
(en)
|
2012-09-28 |
2016-08-16 |
University Of Washington Through Its Center For Commercialization |
Compounds and methods for preventing, treating and/or protecting against sensory hair cell death
|
|
US9512116B2
(en)
|
2012-10-12 |
2016-12-06 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
|
CN113842362A
(zh)
|
2012-11-14 |
2021-12-28 |
格雷斯公司 |
含有生物活性材料与无序无机氧化物的组合物
|
|
JOP20200097A1
(ar)
|
2013-01-15 |
2017-06-16 |
Aragon Pharmaceuticals Inc |
معدل مستقبل أندروجين واستخداماته
|
|
EP2968475A2
(en)
|
2013-03-14 |
2016-01-20 |
Questcor Pharmaceuticals, Inc. |
Acth for treatment of acute respiratory distress syndrome
|
|
TW201521769A
(zh)
|
2013-03-15 |
2015-06-16 |
Durect Corp |
具有流變改質劑以減少溶解變異性之組成物
|
|
WO2014174388A1
(en)
*
|
2013-03-29 |
2014-10-30 |
Wockhardt Limited |
Modified release pharmaceutical compositions of methylphenidate or salts thereof
|
|
WO2014174387A1
(en)
|
2013-03-29 |
2014-10-30 |
Wockhardt Limited |
Modified release pharmaceutical compositions of dexmethylphenidate or salts thereof
|
|
KR20160021277A
(ko)
|
2013-06-19 |
2016-02-24 |
세라곤 파마슈티컬스, 인크. |
에스트로겐 수용체 조절제 및 이의 용도
|
|
CA2915534A1
(en)
|
2013-06-19 |
2014-12-24 |
Seragon Pharmaceuticals, Inc. |
Azetidine estrogen receptor modulators and uses thereof
|
|
US9611263B2
(en)
|
2013-10-08 |
2017-04-04 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
|
JP6345786B2
(ja)
|
2013-12-05 |
2018-06-20 |
ファーマサイクリックス エルエルシー |
ブルトン型チロシンキナーゼの阻害剤
|
|
WO2015148538A1
(en)
*
|
2014-03-24 |
2015-10-01 |
Kashiv Pharma, Llc |
Method of manufacturing fine particles suitable for orally disintegrating pharmaceutical dosage forms
|
|
US20170216328A1
(en)
|
2014-04-04 |
2017-08-03 |
Ritter Pharmaceuticals, Inc. |
Methods and compositions for microbiome alteration
|
|
TW201603818A
(zh)
|
2014-06-03 |
2016-02-01 |
組織科技股份有限公司 |
組成物及方法
|
|
US9839644B2
(en)
|
2014-09-09 |
2017-12-12 |
ARKAY Therapeutics, LLC |
Formulations and methods for treatment of metabolic syndrome
|
|
CA2902911C
(en)
|
2014-10-31 |
2017-06-27 |
Purdue Pharma |
Methods and compositions particularly for treatment of attention deficit disorder
|
|
US9359316B1
(en)
|
2014-11-25 |
2016-06-07 |
Concentric Analgesics, Inc. |
Prodrugs of phenolic TRPV1 agonists
|
|
ES2760373T3
(es)
|
2015-02-06 |
2020-05-13 |
Univ Washington |
Compuestos y procedimientos para prevenir o tratar la muerte de células ciliadas sensoriales
|
|
US10227333B2
(en)
|
2015-02-11 |
2019-03-12 |
Curtana Pharmaceuticals, Inc. |
Inhibition of OLIG2 activity
|
|
US20160243288A1
(en)
|
2015-02-23 |
2016-08-25 |
Tissuetech, Inc. |
Apparatuses and methods for treating ophthalmic diseases and disorders
|
|
BR112017018198A2
(pt)
|
2015-02-27 |
2018-04-10 |
Curtana Pharmaceuticals Inc |
inibição da atividade de olig2
|
|
US10342831B2
(en)
|
2015-05-20 |
2019-07-09 |
Tissuetech, Inc. |
Composition and methods for preventing the proliferation and epithelial-mesenchymal transition of epithelial cells
|
|
US11590228B1
(en)
|
2015-09-08 |
2023-02-28 |
Tris Pharma, Inc |
Extended release amphetamine compositions
|
|
EP3368543B1
(en)
|
2015-10-26 |
2020-09-23 |
MAX Biopharma, Inc. |
Oxysterols and hedgehog signaling
|
|
US9637514B1
(en)
|
2015-10-26 |
2017-05-02 |
MAX BioPharma, Inc. |
Oxysterols and hedgehog signaling
|
|
EP3389695A4
(en)
|
2015-12-16 |
2019-10-09 |
The Walter and Eliza Hall Institute of Medical Research |
INHIBITION OF CYTOKININDUCED SH2 PROTEIN IN NK CELLS
|
|
TWI726969B
(zh)
|
2016-01-11 |
2021-05-11 |
比利時商健生藥品公司 |
用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
|
|
TW201733600A
(zh)
|
2016-01-29 |
2017-10-01 |
帝聖工業公司 |
胎兒扶持組織物及使用方法
|
|
CA3055170A1
(en)
|
2016-03-04 |
2017-09-08 |
Charleston Laboratories, Inc. |
Pharmaceutical compositions
|
|
CA3025268A1
(en)
|
2016-05-25 |
2017-11-30 |
Concentric Analgesics, Inc. |
Prodrugs of phenolic trpv1 agonists in combination with local anesthetics and vasoconstrictors for improved local anesthesia
|
|
WO2017205762A1
(en)
|
2016-05-27 |
2017-11-30 |
Pharmacyclics Llc |
Inhibitors of interleukin-1 receptor-associated kinase
|
|
WO2017205769A1
(en)
|
2016-05-27 |
2017-11-30 |
Pharmacyclics Llc |
Inhibitors of interleukin-1 receptor-associated kinase
|
|
WO2017205766A1
(en)
|
2016-05-27 |
2017-11-30 |
Pharmacyclics Llc |
Inhibitors of interleukin-1 receptor-associated kinase
|
|
US12274794B2
(en)
|
2016-07-06 |
2025-04-15 |
Orient Pharma Co., Ltd. |
Oral dosage form with drug composition, barrier layer and drug layer
|
|
SG11201901679XA
(en)
|
2016-08-26 |
2019-03-28 |
Curtana Pharmaceuticals Inc |
Inhibition of olig2 activity
|
|
BR112019011640B1
(pt)
|
2016-12-11 |
2021-08-17 |
Kempharm, Inc |
Compostos conjugados de d-metilfenidato, composições que compreendem os mesmos e kit farmacêutico que compreende as ditas composições
|
|
EP3372225A1
(en)
|
2017-03-09 |
2018-09-12 |
Develco Pharma Schweiz AG |
Novel dosage form
|
|
US11590081B1
(en)
|
2017-09-24 |
2023-02-28 |
Tris Pharma, Inc |
Extended release amphetamine tablets
|
|
US12458592B1
(en)
|
2017-09-24 |
2025-11-04 |
Tris Pharma, Inc. |
Extended release amphetamine tablets
|
|
UA129105C2
(uk)
|
2017-10-16 |
2025-01-15 |
Арагон Фармасьютикалз, Інк. |
Антиандрогени для лікування неметастатичного резистентного до кастрації раку передміхурової залози
|
|
CN112739345A
(zh)
|
2017-11-06 |
2021-04-30 |
斯奈普生物公司 |
Pim激酶抑制剂组合物，方法和其用途
|
|
WO2019118984A2
(en)
|
2017-12-15 |
2019-06-20 |
Solarea Bio, Inc. |
Microbial compositions and methods for treating type 2 diabetes, obesity, and metabolic syndrome
|
|
WO2019169112A1
(en)
|
2018-02-28 |
2019-09-06 |
Curtana Pharmaceuticals, Inc. |
Inhibition of olig2 activity
|
|
KR20250111409A
(ko)
|
2018-04-30 |
2025-07-22 |
세다르스-신나이 메디칼 센터 |
염증성 질환을 보유하는 환자의 선택 및 치료를 위한 방법 및 시스템
|
|
CA3105464A1
(en)
|
2018-07-06 |
2020-01-09 |
Cedars-Sinai Medical Center |
Methods of treating refractory inflammatory disease using transcriptomic and genetic risk signatures
|
|
TW202019887A
(zh)
|
2018-07-27 |
2020-06-01 |
美商同心止痛劑股份有限公司 |
酚系trpv1促效劑之聚乙二醇化前藥
|
|
US11980647B2
(en)
|
2018-09-05 |
2024-05-14 |
Solarea Bio, Inc. |
Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause
|
|
WO2020051379A1
(en)
|
2018-09-05 |
2020-03-12 |
Solarea Bio, Inc. |
Methods and compositions for treating musculoskeletal diseases
|
|
US10722473B2
(en)
|
2018-11-19 |
2020-07-28 |
Purdue Pharma L.P. |
Methods and compositions particularly for treatment of attention deficit disorder
|
|
CN114040760B
(zh)
|
2018-12-31 |
2025-05-09 |
拜欧米富士恩公司 |
Menin-mll相互作用的不可逆抑制剂
|
|
BR112021018254A2
(pt)
|
2019-03-15 |
2022-03-15 |
Unicycive Therapeutics Inc |
Derivados de nicorandil
|
|
CN114144224B
(zh)
|
2019-03-26 |
2024-08-09 |
保科特纳洛克斯恩公司 |
药物合成物输送器械和方法
|
|
KR20220088529A
(ko)
|
2019-05-14 |
2022-06-27 |
프로메테우스 바이오사이언시즈, 인크. |
Tl1a 환자 선택 방법, 시스템 및 장치
|
|
EP3986163A2
(en)
|
2019-06-19 |
2022-04-27 |
Solarea Bio, Inc. |
Microbial compositions and methods for producing upgraded probiotic assemblages
|
|
JP2022537807A
(ja)
|
2019-06-21 |
2022-08-30 |
エンテレクソ バイオセラピューティクス インク． |
治療送達用のプラットフォーム、組成物、および方法
|
|
CA3180628A1
(en)
|
2020-06-03 |
2021-12-09 |
Rebecca GONSKY |
Treatments for a sub-population of inflammatory bowel disease patients
|
|
CA3202151A1
(en)
|
2020-12-16 |
2022-06-23 |
Biomea Fusion, Inc. |
Fused pyrimidine compounds as inhibitors of menin-mll interaction
|
|
CA3204457A1
(en)
|
2021-01-06 |
2022-07-14 |
Ben SESSA |
Mdma in the treatment of alcohol use disorder
|
|
US11278709B1
(en)
|
2021-03-12 |
2022-03-22 |
Pocket Naloxone Corp. |
Drug delivery device and methods for using same
|
|
CA3218884A1
(en)
|
2021-05-11 |
2022-11-17 |
David Nutt |
Therapeutic aminoindane compounds and compositions
|
|
WO2022256720A2
(en)
|
2021-06-03 |
2022-12-08 |
Arcadia Medicine, Inc. |
Enantiomeric entactogen compositions and methods of their use
|
|
US12251385B2
(en)
|
2021-08-11 |
2025-03-18 |
Biomea Fusion, Inc. |
Covalent inhibitors of menin-MLL interaction for diabetes mellitus
|
|
US12180176B2
(en)
|
2021-08-23 |
2024-12-31 |
Alexander Shulgin Research Institute, Inc. |
Fluorinated empathogens
|
|
EP4392028A4
(en)
|
2021-08-23 |
2025-09-24 |
Alexander Shulgin Res Institute Inc |
DEUTERATED EMPATHOGENS
|
|
WO2023027966A1
(en)
|
2021-08-24 |
2023-03-02 |
Biomea Fusion, Inc. |
Pyrazine compounds as irreversible inhibitors of flt3
|
|
US12226408B2
(en)
|
2021-08-31 |
2025-02-18 |
Cerespir Incorporated |
Co-crystals
|
|
EP4396162A4
(en)
|
2021-09-03 |
2025-11-12 |
Alexander Shulgin Res Institute Inc |
ASYMMETRIC ALLYL TRYPTAMINES
|
|
WO2023039240A1
(en)
|
2021-09-13 |
2023-03-16 |
Biomea Fusion, Inc. |
IRREVERSIBLE INHIBITORS OF KRas
|
|
EP4405318A4
(en)
|
2021-09-25 |
2025-11-05 |
Alexander Shulgin Res Institute Inc |
PHENYLAKYLAMINES SUBSTITUTED
|
|
CN114022146A
(zh)
*
|
2021-11-03 |
2022-02-08 |
杭州每刻科技有限公司 |
基于Jasper的网银付款文件的生成方法及系统
|
|
WO2023086341A1
(en)
|
2021-11-09 |
2023-05-19 |
Biomea Fusion, Inc. |
Inhibitors of kras
|
|
CA3238788A1
(en)
|
2021-11-22 |
2023-05-25 |
Eric Michael Schott |
Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause
|
|
US20230190834A1
(en)
|
2021-12-21 |
2023-06-22 |
Solarea Bio, Inc. |
Immunomodulatory compositions comprising microbial entities
|
|
KR20240128987A
(ko)
|
2021-12-30 |
2024-08-27 |
바이오메아 퓨전, 인크. |
Flt3의 억제제로서의 피라진 화합물
|
|
US20250100990A1
(en)
|
2022-01-19 |
2025-03-27 |
Awakn Ls Europe Holdings Limited |
1,3-benzodioxole esters and their therapeutic use
|
|
US20250179089A1
(en)
|
2022-02-16 |
2025-06-05 |
Awakn Ls Europe Holdings Limited |
Bridged ring compounds and their therapeutic use as cns agents
|
|
WO2023235618A1
(en)
|
2022-06-03 |
2023-12-07 |
Biomea Fusion, Inc. |
Fused pyrimidine compounds as inhibitors of menin
|
|
US20250002458A1
(en)
|
2023-05-24 |
2025-01-02 |
Unicycive Therapeutics Inc. |
Salt forms of nicorandil derivative
|
|
WO2024249950A1
(en)
|
2023-06-02 |
2024-12-05 |
Biomea Fusion, Inc. |
Fused pyrimidine compounds as inhibitors of menin
|
|
WO2025072556A1
(en)
|
2023-09-26 |
2025-04-03 |
Unicycive Therapeutics, Inc. |
Amino acid prodrugs of nicorandil
|
|
WO2025194102A1
(en)
|
2024-03-15 |
2025-09-18 |
Unicycive Therapeutics, Inc. |
Pyridine modified nicorandil derivatives
|
|
US12303604B1
(en)
|
2024-10-16 |
2025-05-20 |
Currax Pharmaceuticals Llc |
Pharmaceutical formulations comprising naltrexone and/or bupropion
|